DURHAM – Shattuck Labs, a life science startup focusing on development of new treatments for cancer and autoimmune disease, is going public today and expects to raise $202 million the process.
The company in June closed on $118 million in new financing and secured Durham-based Hatteras Venture Partners as a backer.
In an announcement made late Thursday, Shattuck said shares would begin trading today on the Nasdaq under the symbol “STTK.”
Shares were priced at $17.
Some 11,882,352 shares were issued with underwriters having the option to purchase another 1.8 million shares.
The company has offices in Durham and Austin, Texas.
More Shattuck headlines
Inside startup Shattuck Labs: Changing the face of cancer therapy
Durham life science startup Shattuck Labs raises $118M, lands Hatteras Ventures as investor
